

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 May 2025 (01.05.2025)



(10) International Publication Number
WO 2025/090702 A1

(51) International Patent Classification:

A61K 31/519 (2006.01) A61P 17/06 (2006.01)
A61P 17/04 (2006.01) A61K 45/06 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2024/052716

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(22) International Filing Date:

24 October 2024 (24.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/593,108 25 October 2023 (25.10.2023) US
63/606,912 06 December 2023 (06.12.2023) US
63/697,819 23 September 2024 (23.09.2024) US

(71) Applicant: **PRINCIPIA BIOPHARMA INC.** [US/US];
55 Corporate Drive, Bridgewater, New Jersey 08807 (US).

(72) Inventors: **BARET-CORMEL, Lydie**; c/o Sanofi, Patent
Department, 46 avenue de la Grande Armée, 75017 Paris
(FR). **MANNENT, Leda**; c/o Sanofi, Patent Department,
46 avenue de la Grande Armée, 75017 Paris (FR). **MIKOL,
Vincent**; c/o Sanofi, Patent Department, 46 avenue de la
Grande Armée, 75017 Paris (FR).

(74) Agent: **WINKLER, Lauren N.** et al.; McNeill PLLC, 245
First Street, 18th Floor, Cambridge, Massachusetts 02142
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: RILZABRUTINIB FOR USE IN THE TREATMENT OF ITCH ASSOCIATED WITH ATOPIC DERMATITIS AND/OR PRURIGO NODULARIS

(57) Abstract: Methods for treating itch in human patients with atopic dermatitis (AD) and/or prurigo nodularis (PN) comprising administering a therapeutically effective amount of at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (rilzabrutinib) and pharmaceutically acceptable salts thereof are disclosed.

WO 2025/090702 A1